Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2015-10-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2015年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow, and shareholder information. The length of the document (8724 characters) and the presence of substantive financial data and analysis confirm it is a full interim/quarterly report rather than a brief announcement or certification. There is no indication that this is an annual report or an earnings release summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2015
2015-10-29 Chinese
2015年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder information. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2015
2015-10-29 Chinese
关于控股子公司取得破伤风疫苗临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (485 characters) about a subsidiary obtaining a clinical trial approval for a vaccine. It is a regulatory update related to the company's operations but does not contain financial data, management changes, voting results, or detailed financial reports. It is not a report itself but an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2015-10-28 Chinese
关于重庆巫溪县单采血浆站文峰分站取得单采血浆许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the receipt of a plasma collection license by a subsidiary of the company. It is a regulatory announcement about an operational permit, not a financial report, management change, or shareholder meeting material. The document length is only 415 characters, indicating it is a brief notice. It does not contain financial data, voting results, or executive changes. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2015-10-27 Chinese
关于重庆开县单采血浆站南门分站取得单采血浆许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (406 characters) regarding the receipt of a plasma collection license by a subsidiary of the company. It is a regulatory announcement about a permit/license obtained, not a financial report, management change, or voting result. It does not contain financial data or detailed report content. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2015-10-08 Chinese
关于限制性股票激励计划首次授予第二期及预留授予第一期限制性股票解锁上市流通的提示性公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the unlocking and listing of restricted shares under a stock incentive plan. It includes specifics about the number of shares unlocked, the conditions met for unlocking, board and supervisory committee approvals, legal opinions, and detailed tables of share allocations to executives and employees. The document is not a financial report, earnings release, or regulatory filing about financial results. It is a formal announcement related to share transactions involving restricted stock becoming tradable, which fits the category of Transaction in Own Shares (POS). The document length is sufficient and contains substantive content about the share unlocking event, not just a brief notice or report publication announcement.
2015-09-09 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.